In the article "Understanding caregiver goals, benefits, and acceptable risks of peanut allergy therapies,"1 the authors undertake the ambitious task of using qualitative research methods to describe the motivation and goals of caregivers of children with peanut allergy. This is a critically important area given the rapid increase in peanut allergy in the past 2 decades and the development of 2 different immunotherapy products, one or both of which will likely be approved by the US Food and Drug Administration and available for prescription by late 2019.
https://ift.tt/2DcGLiL
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου